Are you ready for ESMO23 in Madrido?!

It’s time to kick off our latest meeting previews highlighting some of the research being presented at the upcoming ESMO23 cancer conference in Madrid.

In the first of the series we take a critical look at some of the verbiage being used in the abstract titles and examine whether or not they hold up under the microscope.

We found some of the research doesn’t appear to actually represent major scientific advances, despite being labelled as such.

The key takeaway here is claims should be carefully scrutinised when evaluating early stage cancer research. Hard data and rigour are still essential to determine if something represents a real therapeutic advance versus hype.

The provocative question we address for readers is which abstracts fall into which category?

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by